Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
SingaporeIPO:
04 May 2018Website:
http://aslanpharma.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:55:22 GMTDividend
Analysts recommendations
Institutional Ownership
ASLN Latest News
ASLAN Pharmaceuticals (ASLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ASLAN Pharmaceuticals (ASLN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Here is the performance of ASLAN Pharmaceuticals Ltd. (ASLN) and Assembly Biosciences (ASMB) compared to their sector year to date.
ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.
ASLAN (ASLN) reports mixed results from a mid-stage study of eblasakimab in adult patients with moderate-to-severe atopic dermatitis. The stock price of the company fell by 25%.
Shares of Aslan Pharmaceuticals ASLN were down 32% premarket on Thursday after the company released new data from a clinical study of eblasakimab, an atopic dermatitis treatment. Among patients treated with the highest dose of the monoclonal antibody once every four weeks, 63% achieved at least a 75% reduction in an eczema area and severity index, the company said in a release, compared to 31% on placebo.
SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023, at 8:30 am ET. Management will host a question and answer session following the formal presentation.
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Sanofi (SNY) have performed compared to their sector so far this year.
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Atreca, Inc. (BCEL) have performed compared to their sector so far this year.
What type of business is ASLAN Pharmaceuticals Limited?
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
What sector is ASLAN Pharmaceuticals Limited in?
ASLAN Pharmaceuticals Limited is in the Healthcare sector
What industry is ASLAN Pharmaceuticals Limited in?
ASLAN Pharmaceuticals Limited is in the Biotechnology industry
What country is ASLAN Pharmaceuticals Limited from?
ASLAN Pharmaceuticals Limited is headquartered in Singapore
When did ASLAN Pharmaceuticals Limited go public?
ASLAN Pharmaceuticals Limited initial public offering (IPO) was on 04 May 2018
What is ASLAN Pharmaceuticals Limited website?
https://aslanpharma.com
Is ASLAN Pharmaceuticals Limited in the S&P 500?
No, ASLAN Pharmaceuticals Limited is not included in the S&P 500 index
Is ASLAN Pharmaceuticals Limited in the NASDAQ 100?
No, ASLAN Pharmaceuticals Limited is not included in the NASDAQ 100 index
Is ASLAN Pharmaceuticals Limited in the Dow Jones?
No, ASLAN Pharmaceuticals Limited is not included in the Dow Jones index
When does ASLAN Pharmaceuticals Limited report earnings?
The next expected earnings date for ASLAN Pharmaceuticals Limited is 09 August 2024